RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL)
Clinical trials for RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial offers hope for Tough-to-Treat blood cancer patients
Disease control Recruiting nowThis study is testing an experimental drug called ICP-248 for adults with mantle cell lymphoma, a type of blood cancer, that has returned or stopped responding to previous treatments. The trial will measure how well the drug shrinks tumors and controls the cancer, while monitorin…
Matched conditions: RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New hope for Tough-to-Treat blood cancer patients
Disease control Recruiting nowThis study is testing whether a combination of two drugs, glofitamab and lenalidomide, can help control a hard-to-treat type of blood cancer called mantle cell lymphoma. It is for patients whose cancer has come back or stopped responding to previous treatments, including a specif…
Matched conditions: RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE2 • Sponsor: Peking University Third Hospital • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC